FDA's Risky Prescription for Compounding Pharmacies The Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC) recently voted to add four peptides to the list of substances compounding pharmacies can make, despite opposition from agency scientists.
The decision has raised concerns about the FDA's commitment to ensuring public safety in the face of commercial pressure.
The peptides in question – BPC 157, KPV, TB 500, and MOTS c – are already widely available online for human use, often without evidence supporting their efficacy.